KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 78 filers reported holding KALVISTA PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $118,353 | +10.9% | 12,290 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $106,677 | +14.9% | 11,853 | +0.3% | 0.00% | 0.0% |
| Q1 2023 | $92,858 | +18.6% | 11,814 | +2.0% | 0.00% | 0.0% |
| Q4 2022 | $78,274 | -53.7% | 11,579 | -0.4% | 0.00% | 0.0% |
| Q3 2022 | $169,000 | +49.6% | 11,621 | +1.4% | 0.00% | 0.0% |
| Q2 2022 | $113,000 | -31.1% | 11,456 | +3.0% | 0.00% | 0.0% |
| Q1 2022 | $164,000 | +4.5% | 11,119 | -6.6% | 0.00% | 0.0% |
| Q4 2021 | $157,000 | -17.4% | 11,901 | +9.4% | 0.00% | 0.0% |
| Q3 2021 | $190,000 | -28.8% | 10,880 | -2.3% | 0.00% | 0.0% |
| Q2 2021 | $267,000 | -6.3% | 11,139 | +0.3% | 0.00% | 0.0% |
| Q1 2021 | $285,000 | +77.0% | 11,105 | +30.9% | 0.00% | 0.0% |
| Q4 2020 | $161,000 | +56.3% | 8,486 | +4.1% | 0.00% | – |
| Q3 2020 | $103,000 | +2.0% | 8,154 | -2.2% | 0.00% | – |
| Q2 2020 | $101,000 | +77.2% | 8,340 | +11.6% | 0.00% | – |
| Q1 2020 | $57,000 | -59.6% | 7,472 | -5.5% | 0.00% | -100.0% |
| Q4 2019 | $141,000 | +64.0% | 7,903 | +7.2% | 0.00% | – |
| Q3 2019 | $86,000 | -47.6% | 7,371 | -0.7% | 0.00% | -100.0% |
| Q2 2019 | $164,000 | – | 7,421 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
| TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
| TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
| VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
| Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
| Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
| DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
| Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
| MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |